All In Biotech

Drug Trial Radar · NCT03606967

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

Randomized Phase 2 Clinical Trial of Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab + Neoantigen Vaccine vs. Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab in Patients With Metastatic Triple Negative Breast Cancer

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

86

Planned (sponsor's estimate)

Start

Apr 13, 2021

Primary completion

Dec 30, 2026

Study completion Dec 30, 2026

Sponsor

Sponsor type
NIH
First posted
Jul 31, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, care provider)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial studies how well nab-paclitaxel, durvalumab, and tremelimumab with or without personalized synthetic long peptide vaccine (neoantigen vaccine) works in treating patients with triple negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as durvalumab and tremelimumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. It is not yet known whether giving nab-paclitaxel, durvalumab, and tremelimumab with or without neoantigen vaccine will work better in treating patients with triple negative breast cancer.

Conditions

  • Anatomic Stage IV Breast Cancer AJCC v8
  • Invasive Breast Carcinoma
  • Metastatic Triple-Negative Breast Carcinoma

Interventions

  • Biopsy ProcedureProcedure

    Undergo tumor biopsy

  • Biospecimen CollectionProcedure

    Undergo blood and urine sample collection

  • CarboplatinDrug

    Given IV

  • Computed TomographyProcedure

    Undergo CT scan

  • DurvalumabBiological

    Given IV

  • Gemcitabine HydrochlorideDrug

    Given IV

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • Nab-paclitaxelDrug

    Given IV

  • Personalized Synthetic Long Peptide VaccineBiological

    Given SC

  • Poly ICLCDrug

    Given SC

  • Sacituzumab GovitecanBiological

    Given IV

  • TremelimumabBiological

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS)Time frame: From initiation of Part B to progression or death, assessed at 6 and 12 months

Locations

30 sites in 1 country. Site status is shown where the registry gives one.

  • UC Irvine Health/Chao Family Comprehensive Cancer Center

    Orange, California · Active not recruiting

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California · Terminated

  • UCHealth University of Colorado Hospital

    Aurora, Colorado · Recruiting

  • Smilow Cancer Hospital Care Center at Saint Francis

    Hartford, Connecticut · Active not recruiting

  • Yale University

    New Haven, Connecticut · Active not recruiting

  • UM Sylvester Comprehensive Cancer Center at Aventura

    Aventura, Florida · Recruiting

  • UM Sylvester Comprehensive Cancer Center at Coral Gables

    Coral Gables, Florida · Recruiting

  • UM Sylvester Comprehensive Cancer Center at Deerfield Beach

    Deerfield Beach, Florida · Recruiting

  • University of Miami Miller School of Medicine-Sylvester Cancer Center

    Miami, Florida · Recruiting

  • UM Sylvester Comprehensive Cancer Center at Kendall

    Miami, Florida · Recruiting

  • UM Sylvester Comprehensive Cancer Center at Plantation

    Plantation, Florida · Recruiting

  • Moffitt Cancer Center-International Plaza

    Tampa, Florida · Recruiting

  • Moffitt Cancer Center - McKinley Campus

    Tampa, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Moffitt Cancer Center at Wesley Chapel

    Wesley Chapel, Florida · Recruiting

  • Johns Hopkins University/Sidney Kimmel Cancer Center

    Baltimore, Maryland · Recruiting

  • Siteman Cancer Center at Saint Peters Hospital

    City of Saint Peters, Missouri · Recruiting

  • Siteman Cancer Center at West County Hospital

    Creve Coeur, Missouri · Recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

  • Siteman Cancer Center-South County

    St Louis, Missouri · Recruiting

  • Siteman Cancer Center at Christian Hospital

    St Louis, Missouri · Recruiting

  • Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center

    Lebanon, New Hampshire · Suspended

  • NYP/Weill Cornell Medical Center

    New York, New York · Recruiting

  • Wake Forest University at Clemmons

    Clemmons, North Carolina · Recruiting

  • Wake Forest University Health Sciences

    Winston-Salem, North Carolina · Recruiting

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio · Recruiting

  • University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma · Active not recruiting

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania · Recruiting

  • University of Texas Medical Branch

    Galveston, Texas · Recruiting

  • VCU Massey Comprehensive Cancer Center

    Richmond, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.